| 纯度 | > 85 % SDS-PAGE. |
| 种属 | Human |
| 靶点 | BRD3 |
| Uniprot No | Q15059 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-416aa |
| 氨基酸序列 | MGSSHHHHHH SSGLVPRGSH MGSMSTATTV APAGIPATPG PVNPPPPEVS NPSKPGRKTN QLQYMQNVVV KTLWKHQFAW PFYQPVDAIK LNLPDYHKII KNPMDMGTIK KRLENNYYWS ASECMQDFNT MFTNCYIYNK PTDDIVLMAQ ALEKIFLQKV AQMPQEEVEL LPPAPKGKGR KPAAGAQSAG TQQVAAVSSV SPATPFQSVP PTVSQTPVIA ATPVPTITAN VTSVPVPPAA APPPPATPIV PVVPPTPPVV KKKGVKRKAD TTTPTTSAIT ASRSESPPPL SDPKQAKVVA RRESGGRPIK PPKKDLEDGE VPQHAGKKGK LSEHLRYCDS ILREMLSKKH AAYAWPFYKP VDAEALELHD YHDIIKHPMD LSTVKRKMDG REYPDAQGFA ADVRLMFSNC YKYNPPDHEV VAMARKLQDV FEMRFAKMP |
| 预测分子量 | 48 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于BRD3重组蛋白的3篇参考文献示例(注：以下文献为示例，实际引用时需核实真实性)：
---
1. **文献名称**: *Structural basis of BRD3 activation by phosphorylation and its ligand-binding properties*
**作者**: Smith A, et al.
**摘要**: 该研究解析了BRD3重组蛋白的磷酸化修饰对其活性的影响，通过X射线晶体学揭示了磷酸化位点如何增强其与小分子抑制剂的结合能力，为靶向BRD3的药物设计提供了结构基础。
---
2. **文献名称**: *Recombinant BRD3 bromodomains as tools for epigenetic interaction profiling*
**作者**: Jones B, et al.
**摘要**: 报道了通过大肠杆菌表达系统高效制备重组BRD3溴结构域蛋白的方法，并利用该蛋白进行高通量筛选，鉴定其与组蛋白乙酰化修饰的特异性相互作用，揭示了其在表观遗传调控中的潜在作用。
---
3. **文献名称**: *BRD3 regulates oncogenic gene networks in leukemia through chromatin remodeling*
**作者**: Lee C, et al.
**摘要**: 研究利用重组BRD3蛋白进行染色质免疫沉淀(ChIP)实验，发现其通过与特定转录因子(如MYC)协同作用，调控白血病相关基因的表达，为BRD3在血液肿瘤中的治疗价值提供了证据。
---
**注**：以上文献信息为模拟内容，实际研究中请通过PubMed或Web of Science检索真实文献(如涉及BRD3结构、功能或重组表达的研究)。
BRD3 (Bromodomain-containing protein 3) is a member of the Bromodomain and Extra-Terminal (BET) family of proteins, which play critical roles in regulating gene expression by recognizing acetylated lysine residues on histones and other nuclear proteins. Structurally, BRD3 contains two tandem bromodomains (BD1 and BD2) that enable selective binding to acetylated chromatin, facilitating the recruitment of transcriptional regulators. This interaction links BRD3 to epigenetic modulation of pathways involved in cell proliferation, differentiation, and inflammation.
Recombinant BRD3 protein is engineered in vitro using expression systems like *E. coli*, insect, or mammalian cells to produce a purified, functional form of the protein for research and therapeutic development. Its production enables detailed biochemical and structural studies, such as elucidating bromodomain-ligand binding mechanisms or screening small-molecule inhibitors targeting BET proteins. Dysregulation of BRD3 has been implicated in cancers, inflammatory diseases, and neurological disorders, making it a promising therapeutic target. For example, BET inhibitors disrupting BRD3’s interaction with acetylated histones show potential in oncology by suppressing oncogene expression.
Research using recombinant BRD3 has advanced understanding of its role in chromatin remodeling complexes and transcriptional elongation. Additionally, it aids in studying post-translational modifications that modulate its activity. Despite functional overlap with other BET members (e.g., BRD2. BRD4), BRD3 exhibits unique regulatory roles in specific contexts, such as erythroid differentiation or viral replication. Ongoing studies focus on developing isoform-selective inhibitors to minimize off-target effects, highlighting the importance of recombinant BRD3 in both basic science and drug discovery.
×
